The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study
Abstract
Few data exist to guide treatment of anemic hemodialysis patients with high ferritin and low transferrin saturation (TSAT). The Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) trial was designed to evaluate the efficacy of intravenous ferric gluconate in such patients. Inclusion criteria were hemoglobin or=225 IU/kg per wk or >or=22,500 IU/wk. Patients with known infections or recent significant blood loss were excluded. Participants (n=134) were randomly assigned to no iron (control) or to ferric gluconate 125 mg intravenously with eight consecutive hemodialysis sessions (intravenous iron). At randomization, epoetin was increased 25% in both groups; further dosage changes were prohibited. At 6 wk, hemoglobin increased significantly more (P=0.028) in the intravenous iron group (1.6 +/- 1.3 g/dl) than in the control group (1.1 +/- 1.4 g/dl). Hemoglobin response occurred faster (P=0.035) and more patients responded after intravenous iron than in the control group (P=0.041). Ferritin 800 ng/ml had no relationship to the magnitude or likelihood of responsiveness to intravenous iron relative to the control group. Similarly, the superiority of intravenous iron compared with no iron was similar whether baseline TSAT was above or below the study median of 19%. Ferritin decreased in control subjects (-174 +/- 225 ng/ml) and increased after intravenous iron (173 +/- 272 ng/ml; P<0.001). Intravenous iron resulted in a greater increase in TSAT than in control subjects (7.5 +/- 7.4 versus 1.8 +/- 5.2%; P<0.001). Reticulocyte hemoglobin content fell only in control subjects, suggesting worsening iron deficiency. Administration of ferric gluconate (125 mg for eight treatments) is superior to no iron therapy in anemic dialysis patients receiving adequate epoetin dosages and have a ferritin 500 to 1200 ng/ml and TSAT
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
(2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.03.010 · Cited by 829
Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis
Guyader, D., Jacquelinet, C., Moirand, R., Turlin, B., Mendler, M. H., Chaperon, J., David, V., Brissot, P., Adams, P., & Deugnier, Y. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70265-3 · Cited by 342
Time-Dependent Associations between Iron and Mortality in Hemodialysis Patients
Kalantar-Zadeh, K., Regidor, D. L., McAllister, C. J., Michael, B., & Warnock, D. G. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005040423 · Cited by 285
Adams, P. C., Deugnier, Y., Moirand, R., & Brissot, P. (1997) · Hepatology · doi:10.1002/hep.510250130 · Cited by 241
Diagnosis and Management of Hemochromatosis
Tavill, A. S. (2001) · Hepatology · doi:10.1053/jhep.2001.24783 · Cited by 226
2005 Annual Report: ESRD Clinical Performance Measures Project
Kinney, R. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.07.015 · Cited by 211
Tessitore, N., Solero, G. P., Lippi, G., Bassi, A., Faccini, G. B., Bedogna, V., Gammaro, L., Brocco, G., Restivo, G., Bernich, P., et al. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.7.1416 · Cited by 210
Cited by
Ganz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Macdougall, I. C., Bircher, A. J., Eckardt, K.-U., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiss, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 482
Self-citationHepcidin and disorders of iron metabolism
Ganz, T., & Nemeth, E. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-050109-142444 · Cited by 466
The Safety of Intravenous Iron Preparations
Avni, T., Bieber, A., Grossman, A., Green, H., Leibovici, L., & Gafter-Gvili, A. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.10.007 · Cited by 441
Guidelines for the management of chronic kidney disease
Levin, A., Hemmelgarn, B., Culleton, B., Tobe, S., McFarlane, P., Ruzicka, M., Burns, K., Manns, B., White, C., Madore, F., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080351 · Cited by 420
Metadata
- Authors
- Coyne, D. W., Kapoian, T., Suki, W., Singh, A. K., Moran, J. E., Dahl, N. V., & Rizkala, A. R.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2007-03
- Volume
- 18
- Issue
- 3
- Pages
- 975-984
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2144758554
- Cited by
- 391
- References
- 25
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. https://app.cochat.ai/papers/10.1681/asn.2006091034
- The paper
- Coyne, D. W., Kapoian, T., Suki, W., Singh, A. K., Moran, J. E., Dahl, N. V., & Rizkala, A. R. (2007). Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2006091034
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
